Daily Cardiology Research Analysis
Analyzed 221 papers and selected 3 impactful papers.
Summary
Across cardiology this week: a meta-analysis of randomized trials shows that short-term DOAC therapy after left atrial appendage closure reduces device-related thrombosis and bleeding versus dual antiplatelet therapy without increasing stroke or death. A single-cell and spatial transcriptomic atlas of ascending thoracic aortic aneurysm maps immune-cell hubs and implicates IFN/AP-1/NF-κB signaling in aneurysm remodeling. A national instrumental-variable analysis finds that regions favoring multivessel PCI achieve lower in-hospital mortality but worse long-term outcomes than CABG.
Research Themes
- Post-LAAC antithrombotic strategy optimization with DOACs
- Immune microenvironment and signaling in ascending thoracic aortic aneurysm
- Revascularization strategy and long-term outcomes: PCI versus CABG
Selected Articles
1. Direct Oral Anticoagulants Versus Dual Antiplatelet Therapy Following Left Atrial Appendage Closure in Atrial Fibrillation.
Pooling three RCTs (n=704), short-term DOAC regimens after LAAC reduced device-related thrombosis and bleeding versus DAPT without increasing stroke or all-cause mortality. These findings support DOACs as a favorable early post-implant antithrombotic option in appropriately selected AF patients undergoing LAAC.
Impact: Clarifies a key management gap post-LAAC using randomized evidence, with immediate implications for minimizing device thrombosis and bleeding.
Clinical Implications: For early post-LAAC management, consider short-term DOAC therapy rather than DAPT to lower device-related thrombosis and bleeding risk, while individualizing by renal function, bleeding history, and device type.
Key Findings
- Across three RCTs (ADRIFT, ADALA, ANDES; total n=704), DOACs reduced device-related thrombosis compared with DAPT.
- Short-term DOAC therapy also lowered bleeding events versus DAPT.
- No between-group differences were observed for stroke or all-cause mortality in the early post-implant period.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials
- Consistent direction of effect across trials and outcomes of interest
Limitations
- Small number of RCTs (n=3) and modest total sample size
- Heterogeneity in DOAC regimens, DAPT strategies, and follow-up windows across trials
Future Directions: Head-to-head, adequately powered RCTs comparing standardized DOAC regimens versus DAPT with longer follow-up to evaluate late device thrombosis and clinical events; subgroup analyses by device platform and bleeding risk.
BACKGROUND: Percutaneous left atrial appendage closure (LAAC) is an established alternative to oral anticoagulants for preventing thromboembolic events for selected atrial fibrillation (AF) patients. However, optimal post-procedural antithrombotic therapy remains uncertain, particularly regarding the use of direct oral anticoagulants (DOACs) versus dual antiplatelet therapy (DAPT). OBJECTIVE: This meta-analysis aimed to compare the efficacy and safety outcomes of DOACs versus DAPT in the early post-implant period following LAAC in AF patients. METHODS: We systematically searched PubMed and Embase until November 2025 to identify randomized controlled trials (RCTs) that compared DOACs with DAPT after LAAC. Efficacy outcomes included device-related thrombosis, stroke, and all-cause mortality, whereas safety outcomes encompassed major and minor bleeding. Pooled effect estimates were calculated as odds ratios (ORs) with 95% confidence intervals (CIs). Where appropriate, fixed- or random-effects models were applied according to between-study heterogeneity. RESULTS: Three RCTs (ADRIFT, ADALA, ANDES) involving 704 patients (mean age 75.8-78.4 years; 65% males) were included, with 368 assigned to DOAC and 336 to DAPT. Baseline thromboembolic and bleeding risk were high (mean CHA
2. Spatial and single-cell RNA sequencing reveals the immune microenvironment of human ascending thoracic aortic aneurysms.
By integrating scRNA-seq with high-definition spatial transcriptomics, the authors mapped 187,163 immune cells across ATAA and control aortas, revealing enriched immune infiltrates, robust cell–cell signaling, and candidate therapeutic pathways (interferon/AP-1/NF-κB). The work delineates spatially organized immune programs likely driving aneurysm remodeling.
Impact: Provides the first comprehensive immune-cell and spatial atlas for human ATAA, identifying actionable signaling pathways that could inform targeted anti-inflammatory therapies.
Clinical Implications: While not directly practice-changing yet, the atlas prioritizes interferon/AP-1/NF-κB signaling and immune-cell interactions as targets, guiding biomarker discovery and future trials of targeted anti-inflammatory strategies in ATAA.
Key Findings
- Generated a high-resolution immune cell atlas (187,163 cells) of ATAA and controls with eight major immune cell types.
- Immune cells were significantly enriched in ATAA with strong intercellular signaling networks revealed by CellChat.
- Interferon, AP-1, and NF-κB pathways emerged as candidate therapeutic targets; spatial mapping localized immune programs within the aortic wall.
Methodological Strengths
- Multi-omic integration of single-cell RNA-seq with Visium HD spatial transcriptomics
- Large cell count with computational inference of cell–cell communication (CellChat)
Limitations
- Small patient-level sample size (8 ATAA, 9 controls) and cross-sectional design
- Lack of functional perturbation/validation to prove causality of identified pathways
Future Directions: Translate pathway hits into in situ validation and mechanistic perturbation (e.g., ex vivo human tissue, in vivo models) and develop biomarker-guided trials of targeted anti-inflammatory therapy in ATAA.
BACKGROUND: Ascending thoracic aortic aneurysm (ATAA) is a fatal vascular disease characterized by immune dysregulation. However, the cellular composition, spatial localization, and functional diversity of immune cells in the ATAA microenvironment remain poorly understood. OBJECTIVE: To construct a high-resolution immune cell atlas of human ATAA and explore the immune-mediated vascular remodelling mechanisms associated with its progression. METHOD: We conduct high-throughput single-cell RNA sequencing (scRNA-seq) of aortic tissues from eight ATAA patients and nine controls, including six from the GEO database. In the ATAA group, CD45 RESULTS: A total of 187 163 high-quality immune cells are identified, encompassing eight major immune cell types. Immune cells are significantly enriched in ATAA tissues compared with the controls. CellChat analysis reveals strong immune cell interactions in ATAA, which may contribute to its occurrence and progression. CONCLUSION: This study presents the first high-resolution immune cell atlas of human ATAA, offering novel insights into its immune-mediated vascular remodelling mechanism. KEY POINTS: What is currently known about this topic? ATAA is a vascular disease characterized by medial degeneration and chronic inflammation. Previous single-cell transcriptomic studies have revealed the cellular heterogeneity of the aortic wall and identified alterations in the populations of smooth muscle, fibroblasts and endothelial cells. However, the immune landscape of ATAA remains unclear. Recent single-cell and spatial analyses of aortic dissections and abdominal aortic aneurysms have revealed dynamic immune remodelling involving macrophage polarization, T-cell activation and cytokine-driven matrix degradation. Nevertheless, the spatial resolution of immune heterogeneity and cross-lineage signalling in human ATAA is poorly understood. What is the key research question? This study aimed to determine the cellular composition, spatial distribution and transcriptional reprogramming of immune cell populations in ATAA and to elucidate how the interactions among immune cells lead to inflammation and pathological remodelling of the aortic wall. What is new? Single-cell RNA sequencing combined with Visium HD spatial transcriptomics can comprehensively characterize the composition, gene expression profiles and spatial localizations of eight types of immune cells in the aortic tissues of the control and ATAA groups at the single-cell level. Targeting of the interferon, AP1, and NF-κB pathways is a novel strategy for treating ATAA. The interactions among immune cells have a synergistic effect during ATAA formation, jointly driving immune remodelling. How might this study influence clinical practice? Elucidation of the dynamic differentiation trajectories and gene expression signatures of distinct immune cell populations in normal and ATAA-affected aortas will enhance our understanding of the immunological mechanisms underlying aneurysm pathogenesis. This knowledge provides a foundation for developing targeted anti-inflammatory therapeutic strategies for ATAA.
3. Five-year outcomes of percutaneous coronary intervention and coronary artery bypass grafting for multivessel disease: a national population-based study of regional practice.
In 173,771 multivessel CAD patients with complete 5-year follow-up, regions favoring multivessel PCI achieved lower in-hospital mortality but worse long-term survival compared with CABG, using an instrumental-variable approach based on regional CABG-to-PCI ratios. Findings emphasize that early safety metrics can conflict with long-term effectiveness.
Impact: Large-scale quasi-experimental evidence linking system-level practice patterns to patient survival informs guideline discussions and shared decision-making for multivessel revascularization.
Clinical Implications: For stable multivessel CAD, consider that while PCI may offer lower in-hospital mortality, CABG confers superior long-term survival; patient selection should integrate disease complexity, plaque burden, surgical risk, and patient preferences.
Key Findings
- National cohort of 173,771 multivessel revascularizations (PCI 36.4%, CABG 63.6%) with complete 5-year follow-up.
- Instrumental-variable analysis using regional CABG-to-PCI ratios showed lower in-hospital mortality with PCI but worse long-term survival compared with CABG.
- Highlights discordance between short-term quality metrics and long-term effectiveness in multivessel revascularization strategy.
Methodological Strengths
- Very large national cohort with complete 5-year follow-up
- Instrumental-variable approach to mitigate unmeasured confounding by regional practice preference
Limitations
- Observational design remains susceptible to residual confounding despite IV strategy
- Clinical granularity (e.g., SYNTAX score, completeness of revascularization) may be limited in administrative datasets
Future Directions: Integrate anatomical complexity, plaque burden, and patient-reported outcomes into comparative effectiveness frameworks; assess hybrid and staged strategies; validate findings across health systems.
AIMS: To study how the regional preferences for less invasive multivessel coronary revascularization would adversely affect long-term clinical outcomes. METHODS: A national retrospective cohort study utilizing instrumental variable analysis to estimate the causal effect of revascularization strategy.England, using national linked Hospital Episode Statistics (HES) with office of national statistic mortality data from 2007 to 2020.The analysis included 173 771 individuals with complete 5-year follow-up who underwent multivessel revascularization for coronary artery disease. Of this cohort, 63 189 (36.4%) received percutaneous coronary intervention (PCI) and 110 582 (63.6%) received coronary artery bypass grafting (CABG). In total, 37 894 (21.8%) participants were female, and 153 048 (88.2%) were of White ethnicity.The exposure was the preference between multivessel PCI or CABG. The regional ratio of CABG-to-PCI procedures was used as the instrumental variable.The primary outcome was all-cause mortality, assessed in-hospital and up to 5 years post-procedure. RESULTS: The all-cause mortality was 2.1% ( CONCLUSION: Regional preferences for revascularization with multivessel PCI result in lower in-hospital all-cause mortality, a key quality metric, but worse long-term outcomes for individuals with multivessel coronary artery disease.